Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ventyx Biosciences's share price for the quarter that ended in Dec. 2024 was $2.19. Ventyx Biosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 71.13 Mil. Therefore, Ventyx Biosciences's market cap for the quarter that ended in Dec. 2024 was $155.77 Mil.
Ventyx Biosciences's quarterly market cap
declined
from Jun. 2024 ($163.23 Mil) to Sep. 2024 ($154.06 Mil) but then
increased
from Sep. 2024 ($154.06 Mil) to Dec. 2024 ($155.77 Mil).
Ventyx Biosciences's annual market cap
declined
from Dec. 2022 ($1,868.41 Mil) to Dec. 2023 ($146.32 Mil) but then
increased
from Dec. 2023 ($146.32 Mil) to Dec. 2024 ($155.77 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ventyx Biosciences's Enterprise Value for Today is $-112.64 Mil.
Ventyx Biosciences Market Cap Historical Data
The historical data trend for Ventyx Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ventyx Biosciences's Market Cap
For the Biotechnology subindustry, Ventyx Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ventyx Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ventyx Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Ventyx Biosciences's Market Cap falls into.
Ventyx Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ventyx Biosciences's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ventyx Biosciences (NAS:VTYX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ventyx Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Ventyx Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTYX has been successfully added to your 